Sugi Predict

Sugi Predict / Compounds / SCHEMBL1189634

SCHEMBL1189634

SCHEMBL1189634

C[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H](C)N1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.51
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HPGD P15428 1/20 0.42
▸ SETD7 Q8WTS6 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.40
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21911293 1.00 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDSETD7
SCHEMBL1538186 1.00 NR1H2 (0.51) NR1H2USP2SMN1; SMN2HPGDSETD7
SCHEMBL27031165 0.93 NR1H2 (0.46) NR1H2USP2SMN1; SMN2HPGDSETD7
SCHEMBL20680690 0.84 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDSETD7
SCHEMBL20690384 0.84 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDSETD7
SCHEMBL20690383 0.84 NR1H2 (0.47) NR1H2USP2SMN1; SMN2HPGDSETD7
SCHEMBL15764146 0.84 NR1H2 (0.58) NR1H2USP2SMN1; SMN2HPGDRECQL
SCHEMBL12035619 0.84 NR1H2 (0.58) NR1H2USP2SMN1; SMN2HPGDRECQL
SCHEMBL13801217 0.84 NR1H2 (0.58) NR1H2USP2SMN1; SMN2HPGDRECQL
SCHEMBL15764147 0.84 NR1H2 (0.58) NR1H2USP2SMN1; SMN2HPGDRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119365449-A Compound used as WDR5 inhibitor or pharmaceutically acceptable salt thereof and application thereof 甘李药业股份有限公司 2025-01-24 — — CN disclosed
WO-2024002379-A1 COMPOUND USED AS WDR5 INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE OF COMPOUND 甘李药业股份有限公司 2024-01-04 — — WO disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 — — EP disclosed
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof Beijing Adamadle Biotechnology Limited Liability Company (CN) 2022-06-07 — — US disclosed
EP-3328379-B1 BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION UCB Biopharma SRL (BE) 2021-07-28 — — EP disclosed
US-10975066-B2 Bis-heteroaryl derivatives as modulators of protein aggregation UCB Biopharma SRL (BE) 2021-04-13 — — US disclosed
CN-108707139-B Aminopyrimidine compound and preparation method and application thereof 北京鞍石生物科技有限责任公司 2021-04-06 — — CN disclosed
EP-3313397-B1 PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA MERCK SHARP & DOHME (US) 2020-11-25 — — EP disclosed
US-10669269-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-06-02 — — US disclosed
EP-3640248-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Adamadle Biotechnology Limited Liability Company (CN) 2020-04-22 — — EP disclosed
US-20130116265-A1 COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF ZHANG NAN (CN) 2013-05-09 — — US disclosed
EP-1966146-B1 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS ABBOTT HEALTHCARE PRODUCTS BV (NL) 2011-03-02 — — EP disclosed
US-7893056-B2 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC (US) 2011-02-22 — — US disclosed
US-7521441-B2 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-21 — — US disclosed
US-7521441-B2 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-21 — — US disclosed
CN-101341127-A 4,5-dihydro- (1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators SOLVAY PHARM BV (NL) 2009-01-07 — — CN disclosed
EP-1966146-A1 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS Solvay Pharmaceuticals B.V. (NL) 2008-09-10 — — EP disclosed
US-20070270406-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-11-22 — — US disclosed
WO-2007071662-A1 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS B.V. (NL) 2007-06-28 — — WO disclosed
US-20070142362-A1 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators SOLVAY PHARMACEUTICALS B.V. 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669269-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors MUSK, FGFR1, PDGFRA NR1H2 3102/4885USP2 3883/4885SMN1; SMN2 2205/4885
US-10975066-B2 Bis-heteroaryl derivatives as modulators of protein aggregation HTT, PARK7, SNCA NR1H2 3861/4885USP2 313/4885SMN1; SMN2 141/4885
US-20070142362-A1 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators CNR1, CNR2, GPR55 NR1H2 548/4885USP2 3871/4885SMN1; SMN2 4549/4885
US-20070270406-A1 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors HAVCR2, ZC3HAV1, HCCS NR1H2 145/4885USP2 2842/4885SMN1; SMN2 4349/4885
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof WEE1, WEE2, EGFR NR1H2 3528/4885USP2 4353/4885SMN1; SMN2 4772/4885
US-20130116265-A1 COMPOUND FOR INHIBITING TYPE 5 PHOSPHODIESTERASE AND PREPARATION METHOD THEREOF PDE5A, PDE3B, PDE3A NR1H2 2097/4885USP2 3231/4885SMN1; SMN2 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.